Comparison of clinical cases of patients with exudative form of age-related macular degeneration after standard treatment and refusal of treatment

Alina  Dziuba

doi:10.32345/USMYJ.2(154).2025.58-63

Alina Dziuba Student, O.O. Bogomolets National Medical University, Kyiv, Ukraine

DOI: https://doi.org/10.32345/USMYJ.2(154).2025.58-63

Keywords: Age-Related Macular Degeneration; Optical Coherence Tomography; Ophthalmology; Choroidal Neovascularization; Blindness; exudative age-related macular degeneration, subretinal neovascular membrane, anti-VEGF therapy

Abstract

these clinical cases indicate high effectiveness of using anti-VEGF drug and positive dynamics in the treatment of exudative form of age-related macular degeneration according to standard protocols in patient Ch. and negative dynamics in patient T., who refused treatment. Examination of patients was carried out at the beginning of observation, after 12 and 24 weeks. Visual acuity was examined and optical coherence tomography was performed. In patient Ch. After three intravitreal injections of the anti-VEGF drug aflibercept (once every 4 weeks), visual acuity improved and signs of exudative age-related macular degeneration regressed as assessed by optical coherence tomography scans.

References

Morkhat MB, Marchenko LN, Dalidovich AA. Diagnosis and treatment of age-related macular degeneration. Vitebsk: VSMU; 2015. p.77.

Papadopoulos Z. Recent Developments in the Treatment of Wet Age-related Macular Degeneration. Curr Med Sci [Internet]. 2020 Oct;40(5):851-857.

doi: 10.1007/s11596-020-2253-6

Hobbs SD, Tripathy K, Pierce K. Wet age-related macular degeneration (AMD). StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan. 2024 Aug 11.

Available from: https://www.ncbi.nlm.nih.gov/books/NBK572147/

Sheth JU, Stewart MW, Narayanan R, Anantharaman G, Chandran K, Lai TYY et al. Surv Ophthalmol [Internet]. 2024 Aug 31:S0039-6257(24)00095-X. doi: 10.1016/j.survophthal.2024.08.003.

Ambati J, Fowler BJ. Mechanisms of age-related macular degeneration. Neuron [Internet]. 2012 Jul 12;75(1):26–39. doi: 10.1016/j.neuron.2012.06.018

Marchesi N, Capierri M, Pascale A, Barbieri A. Different Therapeutic Approaches for Dry and Wet AMD. Int J Mol Sci [Internet]. 2024 Dec 4;25(23):13053. doi: 10.3390/ijms252313053

Yla B., Mfa B., Jca B., Li S., Dai X., Shan G., et al. Repurposing bortezomib for choroidal neovascularization treatment via antagonizing vegf-a and pdgf-d mediated signaling. Exp. Eye Res [Internet]. 2021 Mar:204:108446. doi: 10.1016/j.exer.2021.108446.

Marchesi N, Capierri M, Pascale A, Barbieri A. Different Therapeutic Approaches for Dry and Wet AMD. Int J Mol Sci [Internet]. 2024 Dec 4;25(23):13053. doi: 10.3390/ijms252313053

Baumal CR, Sørensen TL, Karcher H, Freitas RL, Becher A, Balez S, et al. Efficacy and safety of brolucizumab in age-related macular degeneration: a systematic review of real-world studies. Acta Ophthalmol [Internet]. 2023 Mar;101(2):123-139. doi: 10.1111/aos.15242

Song D, Liu P, Shang K, Ma Y. Application and mechanism of anti-vegf drugs in age-related macular degeneration. Front Bioeng Biotechnol [Internet]. 2022 Sep 23;10:943915. doi: 10.3389/fbioe.2022.943915